4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stake Reduced by Deep Track Capital LP

Deep Track Capital LP lessened its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 85.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 609,900 shares of the company's stock after selling 3,486,552 shares during the period. Deep Track Capital LP owned approximately 1.32% of 4D Molecular Therapeutics worth $3,397,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of FDMT. Barclays PLC boosted its holdings in 4D Molecular Therapeutics by 141.0% during the third quarter. Barclays PLC now owns 114,848 shares of the company's stock worth $1,241,000 after buying an additional 67,202 shares in the last quarter. Marquette Asset Management LLC acquired a new position in 4D Molecular Therapeutics during the fourth quarter worth $116,000. Peapod Lane Capital LLC acquired a new stake in 4D Molecular Therapeutics in the fourth quarter valued at $806,000. Rhumbline Advisers grew its holdings in 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after purchasing an additional 3,675 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its position in shares of 4D Molecular Therapeutics by 100.0% in the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock valued at $111,000 after buying an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Stock Down 4.9 %

Shares of NASDAQ FDMT traded down $0.16 during trading on Friday, hitting $3.08. 1,055,542 shares of the company traded hands, compared to its average volume of 834,832. 4D Molecular Therapeutics, Inc. has a 1 year low of $2.24 and a 1 year high of $28.93. The firm has a market capitalization of $142.68 million, a P/E ratio of -1.08 and a beta of 2.87. The company has a 50-day moving average price of $3.38 and a 200-day moving average price of $5.29.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.02). Research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

FDMT has been the topic of several recent research reports. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Royal Bank of Canada reduced their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Barclays lowered their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Finally, Morgan Stanley lowered their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.